References

  1. Liver Fact Sheet 2020. World Health Organization. Available at https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed 23 Feb 2021.
  2. China Fact Sheet 2020. World Health Organization. Available at https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed 23 Feb 2021.
  3. Liver Cancer Risk Factors. American Cancer Society. Available at https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html. Accessed 14 Jan 2021.
  4. Up to 10 million people in China could die from chronic hepatitis by 2030 – Urgent action needed to bring an end to the ‘silent epidemic’. World Health Organization. 2016. Available at https://www.who.int/china/news/detail/26-07-2016-up-to-10-million-people-in-china-could-die-from-chronic-hepatitis-by-2030-urgent-action-needed-to-bring-an-end-to-the-silent-epidemic-. Accessed 14 Jan 2021.
  5. Hong Kong Viral Hepatitis Action Plan 2020 – 2024. Hospital Authority. Available at https://www.hepatitis.gov.hk/doc/action_plan/Action%20Plan_Full%20Version_PDF_tc.pdf. Accessed 23 Feb 2021.
  6. Leading Cancer Sites in Hong Kong in 2019. Hong Kong Cancer Registry. Hospital Authority. Available at https://www3.ha.org.hk/cancereg/pdf/top10/rank_2019.pdf. Accessed 13 July 2022.
  7. Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers. 2019;11:841.
  8. Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
  9. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. U.S. Food and Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma. Accessed 27 July 2022.
  10. Summary of opinion: Tecentriq. European Medicines Agency. Available at https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-ii-39_en.pdf. Accessed 27 July 2022.
  11. TECENTRIQ HK Prescribing Information. Roche.
  12. AVASTIN ROCHE HK Prescribing Information. Roche.
  13. IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. Medically. Available at https://medically.roche.com/global/en/asset-viewer.8945ef61-d1ad-4127-8d7b-b50f1527e64e.qr.html?cid=slpsxx2106onhccisvhld2021. Accessed 27 July 2022.
  14. Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer. Roche. Available at https://www.roche.com/media/releases/med-cor-2021-01-12. Accessed 27 July 2022.
  15. Finn R, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine. 2020;382:1894-1905.
  16. Patient-Reported Outcomes From IMbrave150: Better Quality of Life With Doublet. The ASCO Post. Available at https://ascopost.com/issues/february-25-2020/patient-reported-outcomes-from-imbrave150/#:~:text=Patient%2DReported%20Outcomes%20From%20IMbrave150%3A%20Better%20Quality%20of%20Life%20With%20Doublet&text=For%20the%20first%2Dline%20treatment,in%20the%20pivotal%20IMbrave150%20trial. Accessed 25 Jan 2021.
  17. Cancer Expert Working Group on Cancer Prevention and Screening 2016 Recommendations on Prevention and Screening for Liver Cancer For Health Professionals. Available at https://www.chp.gov.hk/files/pdf/liver_cancer_professional.pdf. Accessed 4th May 2021.
  18. El-Serag HB et al. Surveillance for hepatocellular carcinoma: in whom and how? Ther Adv Gastroenterol 2011; 4: 5–10.
  19. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. doi:10.1002/hep.29913
  20. Wang CS, Lin CL, Lee HC, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 2005;11(39):6115-6119. doi:10.3748/wjg.v11.i39.6115
  21. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma., Journal of Hepatology, Volume 69, Issue 1, 2018, Pages 182-236, ISSN 0168-8278; Sherman M. Limitations of screening for hepatocellular carcinoma. Hepat Oncol. 2014;1(2):161–163. doi:10.2217/hep.13.22.
  22. Chan, H. L. Y., et al. (2020). Elecsys PIVKA-II and elecsys AFP assays demonstrate good clinical performance for Hepatocellular Carcinoma (HCC) diagnosis across different disease stages and etiologies. In The Liver Meeting Digital Experience™. AASLD.
  23. Liver Cancer. Cancer Fund. Available at https://www.cancer-fund.org/wp-content/uploads/2021/03/Liver-Cancer-21C-Revamp-Web_s.pdf. Accessed 13 July 2022.
  24. 患上肝癌,怎麼辦:肝癌治療方法簡介. 香港中文大學肝臟護理中心. Available at https://livercenter.com.hk/article/%e6%82%a3%e4%b8%8a%e8%82%9d%e7%99%8c%ef%bc%8c%e6%80%8e%e9%ba%bc%e8%be%a6%ef%bc%9a%e8%82%9d%e7%99%8c%e6%b2%bb%e7%99%82%e6%96%b9%e6%b3%95%e7%b0%a1%e4%bb%8b/. Accessed 13 July 2022.
  25. Treatment. Hong Kong Liver Cancer And Gastrointestinal Cancer Foundation. Available at http://www.hklcf.org/livercancer.php?id=2&pid=8. Accessed 14 Jan 2022.
  26. Liver Cancer. The Hong Kong Anti-cancer Society. Available at https://www.hkacs.org.hk/ufiles/LiverCancer.pdf. Accessed 14 Jan 2022.
  27. How Targeted Therapies Are Used to Treat Cancer. American Cancer Society. Available at https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/what-is.html#:~:text=Targeted%20drugs%20often%20work%20by,that%20have%20already%20been%20made. Accessed 13 July 2022.
  28. What is Targeted Therapy. Cancer.net. Available at https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-targeted-therapy#:~:text=Targeted%20therapy%20is%20a%20type,growth%2C%20like%20blood%20vessel%20cells. Accessed 13 July 2022.
  29. Why Immunotherapy? A Targeted Answer To Cancer. Cancer Research Institute. Available at https://www.cancerresearch.org/en-us/immunotherapy/why-immunotherapy. Accessed 13 July 2022.